 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

---
- 'BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company
  developing cellular therapies for unmet needs, announced today the issuance of a
  Notice of Allowance for a patent from the United States Patent and Trademark Office
  (USPTO) for United States Patent Application No. 15...'


BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury

Lineage Cell Therapeutics, Inc. operates as a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. The company's programs are based on two core proprietary technology platforms: cell replacement and cell and drug delivery. Its cell replacement platform creates new cells and tissues with its pluripotent and progenitor cell technologies. The company's cell and drug delivery programs are based upon its proprietary HyStem cell and drug delivery matrix technology. It engages in the research and development of regenerative medicine or therapeutic products for advancement in the field of oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer and hydrogel products that may be used in surgery and products for human embryonic stem cell research. The company was founded by Judith Segall, Hal Sternberg, Paul E. Segall and Harold D. Waitz on November 30, 1990 and is headquartered in Carlsbad, CA.

Watchers	7,089
52-Wk Low	$0.93
52-Wk High	$1.58

Market Cap	$166.24M
Volume (M)	325,546.00
52-Wk High	$1.58
52-Wk Low	$0.93

Period	Estimated	Reported	Surprise	Result
Q3'23	$-0.05	$-0.04	12.50%	BEAT
Q2'23	$-0.04	$-0.03	32.26%	BEAT
Q1'23	$-0.04	$-0.03	21.05%	BEAT
Q4'22	$-0.04	$-0.03	25.00%	BEAT
Q3'22	$-0.04	$-0.04	-14.29%	MISSED

LCTX Lineage Cell Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals